Psoriatic Arthritis
Conference Coverage
VIDEO: Consider comorbidities when preparing patients for systemic psoriasis therapy
LAS VEGAS – Clinicians should consider the increased risk for multiple comorbidities in their patients with psoriasis, Joel M. Gelfand, MD, said...
Conference Coverage
Optimize anti–TNF-alpha therapy for psoriasis
Anti–TNF-alpha medications have shown effectiveness for psoriasis, but ongoing issues include optimizing therapy, managing treatment in special...
Conference Coverage
VIDEO: IL-23 inhibitors on the upswing
LAS VEGAS
Conference Coverage
Study offers reassuring data on certolizumab use in pregnancy
VIENNA – Consider off-label certolizumab in women with psoriasis who need a biologic and are pregnant or planning to become so.
Conference Coverage
What good are biosimilars if patients won’t use them?
BOSTON – The only meaningful measure of the success of biosimilar drugs for arthritis is whether patients use them.
Conference Coverage
Close monitoring of psoriasis patients can delay PsA onset
NEWPORT BEACH, CALIF. – A patient with psoriasis can develop crippling psoriatic arthritis (PsA) within 5 to 10 years of diagnosis, but monitoring...
From the Journals
PsA bone loss measurement: A surrogate for radiographic progression?
An advanced computer assisted digital x-ray radiogrammetry technique that measures bone thickness has the potential to be a surrogate marker of...
Conference Coverage
Tildrakizumab for psoriasis scores high marks in phase III
VIENNA – Tildrakizumab, a novel biologic for moderate to severe psoriasis, showed favorable efficacy and safety outcomes in two pivotal phase III...
Conference Coverage
Secukinumab for psoriasis at 4 years: undiminished efficacy and safety
VIENNA – Secukinumab showed reassuring safety with no drop-off in efficacy for psoriasis after 4 years of treatment.
Blog
Surgical Risks From Systemic Psoriasis Therapies
Treatment with systemic immunomodulatory agents commonly is employed in patients with moderate to severe plaque psoriasis and psoriatic arthritis...
Conference Coverage
Guselkumab achieves highest-ever response rates in psoriasis
VIENNA